碳酸司维拉姆治疗维持性透析患者高磷血症的有效性、安全性分析  

Analysis of the efficacy and safety of sevelamer carbonate on hyperphosphatemia in patients on maintenance dialysis

作　　者：郑宇 ZHENG Yu(Changji People's Hospital,Changji 831100,China)

机构地区：[1]昌吉市人民医院内分泌/肾病科,831100

出　　处：《中国现代药物应用》2024年第14期133-136,共4页Chinese Journal of Modern Drug Application

摘　　要：目的分析维持性透析患者高磷血症采用碳酸司维拉姆治疗的有效性和安全性。方法60例维持性透析高磷血症患者,采用双盲法将所有患者分为对照组和观察组,每组30例。对照组在基础治疗上给予醋酸钙片口服治疗,观察组在基础治疗上采用碳酸司维拉姆治疗。比较两组患者治疗12周后血钙、血磷、钙磷乘积、甲状旁腺激素水平以及不良反应发生情况。结果治疗12周后,观察组血钙(2.10±0.14)mmol/L、血磷(1.37±0.22)mmol/L、钙磷乘积(35.67±1.19)mg/dl、甲状旁腺激素(220.25±90.10)pg/ml均低于对照组的(2.17±0.11)mmol/L、(1.50±0.26)mmol/L、(40.36±1.18)mg/dl、(275.89±101.14)pg/ml,存在明显差异(P<0.05)。观察组不良反应发生率16.67%低于对照组的40.00%,存在明显差异(P<0.05)。结论对维持性血液透析高磷血症患者,采用碳酸司维拉姆治疗,具有一定安全性和有效性,能够实现对患者血磷水平的调节,降低不良反应发生率,值得在临床中广泛应用。Objective To analyze the efficacy and safety of sevelamer carbonate on hyperphosphatemia in patients on maintenance dialysis.Methods 60 cases of hyperphosphatemia patients on maintenance dialysis were divided into a control group and an observation group by double-blind method,with 30 cases in each group.The control group was treated with calcium acetate tablets,and the observation group was treated with sevelamer carbonate.The blood calcium,blood phosphorus,calcium-phosphorus product,parathyroid hormone levels after 12 weeks of treatment and the occurrence of adverse reactions were compared between the two groups.Results After 12 weeks of treatment,the blood calcium of the observation group was(2.10±0.14)mmol/L,the blood phosphorus(1.37±0.22)mmol/L,the calcium-phosphorus product was(35.67±1.19)mg/dl and the parathyroid hormone was(220.25±90.10)pg/ml,which were all lower than(2.17±0.11)mmol/L,(1.50±0.26)mmol/L,(40.36±1.18)mg/dl and(275.89±101.14)pg/ml of the control group,and there were significant differences(P<0.05).The incidence of adverse reactions in the observation group was 16.67%,which was lower than 40.00%in the control group,and there was significant difference(P<0.05).Conclusion For patients with hyperphosphatemia on maintenance hemodialysis,the treatment with sevelamer carbonate has certain safety and efficacy,which can regulate patients'blood phosphorus level and reduce the incidence of adverse reactions,and is worth to be widely used in the clinic.

关 键 词：碳酸司维拉姆 维持性透析 高磷血症 有效性 安全性 

分 类 号：R692.5[医药卫生—泌尿科学] R589.5[医药卫生—外科学]